Expression level of novel tumor suppressor gene FATS is associated with the outcome of node positive breast cancer

Chinese Medical Journal

Volumn 124, Issue 18, 2011, Pages 2894-2898

  Zhang, Jun ^a   Gu, Lin ^a   Zhao, Lu Jun ^a   Zhang, Xi Feng ^a   Qiu, Li ^a   Li, Zheng ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Biomarker; Breast cancer; Fragile site associated tumor suppressor; Prognosis; Tumor suppressor gene

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CARCINOGENESIS; CONTROLLED STUDY; FATS GENE; GENE DELETION; GENE EXPRESSION; GENETIC CONSERVATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

EID: 80053027495     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.18.018     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Newman LA, Mamounas EP. Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project. Surg Clin North Am 2007; 87: 279-305, vii.
3. Yu KD, Di GH, Wu J, Lu JS, Shen KW, Shen ZZ, et al. Development and trends of surgical modalities for breast cancer in China: a review of 16-year data. Ann Surg Oncol 2007; 9: 2502-2509.
4. Cheang MC, van de Rijn M, Nielsen TO. Gene expression profiling of breast cancer. Annu Rev Pathol 2008; 3: 67-97.
5. Pusztai L, Iwamoto T. Breast cancer prognostic markers in the post-genomic era. Breast Cancer Res Treat 2010; 125: 647-650.
6. Gasser S, Raulet D. The DNA damage response, immunity and cancer. Semin Cancer Biol 2006; 16: 344-347.
7. Arlt MF, Casper AM, Glover TW. Common fragile sites. Cytogenet Genome Res 2003; 100: 92-100.
8. Li Z, Zhang Q, Mao JH, Weise A, Mrasek K, Fan X, et al. An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis. Oncogene 2010; 29: 2659-2671.
9. Maier D, Comparone D, Taylor E, Zhang Z, Gratzl O, Van Meir EG, et al. New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene 1997; 15: 997-1000.
10. Nagase S, Yamakawa H, Sato S, Yajima A, Horii A. Identification of a 790-kilobase region of common allelic loss in chromosome 10q25-q26 in human endometrial cancer. Cancer Res 1997; 57: 1630-1633.
11. Zhang ZH, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Ibusuki M, et al. Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse. Chin Med J 2009; 122: 1764-1768.
12. Li HP, Ji JF, Hou KY, Lei YT, Zhao HM, Wang J, et al. Prediction of recurrence risk in early breast cancer using human epidermal growth factor 2 and cyclin A2. Chin Med J 2010; 123: 431-437.
13. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
14. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005-1018.
15. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998; 90: 1601-1608.
16. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93: 979-989.
17. Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ. Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44: 989-990.
18. Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1539-1569.
19. Joensuu H, Pylkkanen L, Toikkanen S. Long-term survival in node-positive breast cancer treated by locoregional therapy alone. Br J Cancer 1998; 78; 795-799.
20. Zhang X, Zhang Q, Zhang J, Qiu L, Yan SS, Feng J, et al. FATS is a transcriptional target of p53 and associated with antitumor activity. Mol Cancer 2010; 9: 244.
21. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
22. Dulic V, Stein GH, Far DF, Reed SI. Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol 1998; 18: 546-557.
23. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, et al. Prognostic value of p21 (WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996; 2: 1591-1599.
24. Thor AD, Liu S, Moore DH, Shi Q, Edgerton SM. P21 (WAF1/CIP1) expression in breast cancers: associations with p53 and outcome. Breast Cancer Res Treat 2000; 61: 33-43.
25. Derenzini M, Ceccarelli C, Santini D, Taffurelli M, Trere D. The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status. J Clin Pathol 2004; 57: 755-761.
26. Konigsberg R, Rogelsperger O, Jager W, Thalhammer T, Klimpfinger M, Santis MD, et al. Cell cycle dysregulation influences survival in high risk breast cancer patients. Cancer Invest 2008; 26: 734-740.